| P50 | author | Jaclyn F Hechtman | Q57693326 |
| P2093 | author name string | Nikolaus Schultz | |
| | David B Solit | |
| | Marinela Capanu | |
| | Michael F Berger | |
| | Marc Ladanyi | |
| | Jian Zheng | |
| | David M Hyman | |
| | Vivian E Strong | |
| | Debra A Goldman | |
| | Laura H Tang | |
| | Yelena Y Janjigian | |
| | Jonathan M Hernandez | |
| | Jeremy L Davis | |
| | R Taylor Ripley | |
| | Teresa S Kim | |
| | Kaitlin McLaughlin | |
| | Elke J A H van Beek | |
| P2860 | cites work | MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast Cancer | Q26775086 |
| | The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer | Q27824864 |
| | Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 |
| | p53 mutations in human cancers | Q28302973 |
| | Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). | Q30873972 |
| | p53 and human cancer: the first ten thousand mutations. | Q33767112 |
| | Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group | Q34609661 |
| | Effects of individual-level socioeconomic factors on racial disparities in cancer treatment and survival: findings from the National Longitudinal Mortality Study, 1979-2003. | Q34961124 |
| | Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology | Q35584856 |
| | Disparities in gastric cancer chemotherapy between the East and West | Q36472210 |
| | TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes | Q36777326 |
| | TP53 status and response to chemotherapy in breast cancer | Q37188288 |
| | Targeting triple negative breast cancer: is p53 the answer? | Q38074211 |
| | Triple-negative breast cancer: investigating potential molecular therapeutic target | Q38259322 |
| | An overview of triple-negative breast cancer. | Q38581133 |
| | Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities | Q39972544 |
| | Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. | Q41038524 |
| | Race influences stage-specific survival in gastric cancer | Q41247214 |
| | Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. | Q53477269 |
| | Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients | Q71169983 |
| | Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy | Q71563602 |
| | Is gastric carcinoma different between Japan and the United States? | Q73370159 |
| | The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer | Q75216726 |
| | Etiology and prevention of gastric cancer: a population study in a high risk area of China | Q81396511 |
| P433 | issue | 7 | |
| P304 | page(s) | 2027-2033 | |
| P577 | publication date | 2018-05-03 | |
| P1433 | published in | Annals of Surgical Oncology | Q2853069 |
| P1476 | title | Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer | |
| P478 | volume | 25 | |